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Implication for health policy/practice/research/medical education:
Diabetic dermopathy is prevalent and generally takes place before retinopathy and nephropathy. Few studies have so far 
investigated the association between systemic complications of  diabetes such as retinopathy and nephropathy and obtained 
inconsistent findings. Since diabetic dermopathy takes place before retinopathy and nephropathy if  the association between 
diabetic dermopathy with retinopathy and nephropathy in diabetic patients is confirmed, early diagnosis of  dermopathy could 
be to prevent retinopathy and nephropathy. This study confirms the association of  diabetic dermopathy with retinopathy and 
nephropathy and suggests dermopathy as a usable clinical finding in early diagnosis of  retinopathy and nephropathy in patients 
with type 2 diabetes.
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Background: Diabetic dermopathy is one of the most prevalent skin complications in diabetes 
patients. Some studies have pointed to association of diabetic dermopathy with retinopathy 
and nephropathy in patients with type 2 diabetes as microangiopathy presentations, but no 
rigorous study has been conducted to confirm this association. 
Objectives: This study investigated association of diabetic dermopathy with nephropathy and 
retinopathy in patients with type 2 diabetes referring specialty clinic of Shahrekord.
Patients and Methods: This descriptive, cross-sectional study was conducted on 102 
type 2 diabetes patients with dermopathy referring clinic constantly or as outpatient. 
Dermatological and ophthalmological examinations and examination for nephropathy were 
done for all patients. Demographic data and results of examinations and patients history, 
and biochemical tests were gathered and recorded by researcher developed checklists.
Results: Mean age of patients was 83.8 2.60 years, of whom 64 (63.7%) were female and 
37.3% were male. Prevalence of retinopathy in patients was 4.31% and nephropathy 3.33%. 
In this study, significant associations of diabetic dermopathy with diabetic nephropathy 
(P = 0.001), with retinopathy (P < 0.001), age (P < 0.001), duration of diabetes (P = 0.001), 
and also with glycosylated hemoglobin (P < 0.01) was detected. No significant association 
between diabetic dermopathy and other studied variables was seen (P > 0.05).
Conclusions: Results of this study confirm the association of diabetic dermopathy with 
retinopathy and nephropathy in patients with type 2 diabetes. Since dermopathy is usually 
developed before retinopathy and nephropathy, dermopathy could be used as a clinical 
finding in early diagnosis and prevention of retinopathy and nephropathy in diabetes 
patients.
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1. Background 
The chronic complications of  diabetes are divided 
into two types, vascular and non-vascular. The vascu-
lar complications could be microvascular (retinopa-
thy, neuropathy, and nephropathy) and macrovascular 
(coronary artery disease, peripheral artery disease, and 
cerebrovascular disease). Non vascular complications 
include infection and skin and joint lesions, as well. 
Many of  the patients with type 2 diabetes have some 
of  these complications at diagnosis because type 2 dia-
betes is characterized by a long, asymptomatic period. 
As hyperglycemia persists, chronic complications of 
diabetes frequently observed since the second decade 
of  hyperglycemia increase. Microvascular complica-
tions of  type 1 and type 2 diabetes are usually devel-
oped because of  chronic hyperglycemia and therefore 
prevention of  chronic hyperglycemia helps to prevent 
and/or delay the incidence of  retinopathy, neuropa-
thy, and nephropathy. The role of  hyperglycemia in 
development of  macrovascular is less obvious but 
dyslipidemia and hypertension contribute significantly 
to incidence of  macrovascular complications (1-4).
Diabetic retinopathy as a chronic complication of  di-
abetes plays a significant role in declining the quality 
of  life in diabetes patients and is an important reason 
for blindness in the active populations of  the West (5). 
Retinopathy does not take place in the youth popula-
tion with type 1 diabetes for at least 5-10 years after 
the onset of  diabetes. However the patients with type 
2 diabetes may have retinopathy at diagnosis (6). In 
a review article analyzing the findings of  the studies 
conducted in 33 countries worldwide, the prevalence 
of  diabetic retinopathy in the patients already diag-
nosed with hepatitis was reported 9.27% and in those 
recently diagnosed with diabetes 6.16% (7). The di-
agnosis and treatment of  the resulted changes before 
decrease in vision could prevent the blindness due 
to diabetes (8). Another macrovascular complication 
of  chronic diabetes is diabetic nephropathy which is 
the main reason for end stage renal disease in 30% of 
the patients with type 1 diabetes and 20% of  those 
with type 2 diabetes. Approximately 40%-45% of  the 
diabetes patients clearly present with the symptoms 
of  diabetic nephropathy in lifetime (9,10). Out of  the 
microvascular complications, diabetic dermopathy is 
the most prevalent skin presentation (11,12), including 
hyperpigmented and atrophic macules or papules with 
no sharp border and usually occurring on the front leg 
in diabetes patients. These lesions are asymptomatic 
and often do not cause pain and itching. The diagno-
sis of  diabetic dermopathy is clinical and is made by 
description and physical examination. The occurrence 
of  scars and hyperpigmented, atrophic spots with 
sharp borders on the legs of  a diabetes patients is very 
likely to result in diagnosis with diabetic dermopathy 
(11,13,14). Diabetic dermopathy has been reported 
9%-55% prevalent and is likely to be more prevalent 
in the patients over 50 years and with longer dura-
tion of  diabetes. Meanwhile, it occurs usually before 
diabetic retinopathy and nephropathy (12,15). Genet-
ic predisposition could contribute to developing most 
of  the complications because retinopathy or neurop-
athy does not occur in some of  the patients with pro-
longed duration of  diabetes. However the mortality 
from heart coronary disease is two to four times high-
er in the patients with type 2 diabetes. These events 
are associated with fasting blood sugar, non-fasting 
blood sugar, and also HbA1c (16-18) and hence all the 
factors involved in developing sensitive complications 
should be studied.
Several studies have examined the association be-
tween retinopathy and nephropathy in diabetes pa-
tients, most of  which have considered the incidence 
of  retinopathy as necessary for nephropathy diagnosis 
(9,19,20). However few studies have so far investigat-
ed the association between diabetic dermopathy and 
certain predisposing demographic characteristics and 
also other systemic complications of  diabetes such as 
retinopathy and nephropathy and obtained inconsis-
tent findings. Some of  them reported an association 
and some others found no or statistically insignificant 
association (14,17,21-24).  Therefore since diabet-
ic dermopathy is prevalent and generally takes place 
before retinopathy and nephropathy, early diagnosis 
of  dermopathy could help to predict the incidence 
of  retinopathy and nephropathy, delay their incidence 
and adverse and dangerous consequences, or slow 
down their progression by managing diabetes and 
other factors more efficiently if  the association be-
tween dermopathy and incidence of  retinopathy and 
nephropathy is confirmed in the patients with type 2 
diabetes.
2. Objectives
This study aimed to more closely examine and proba-
bly confirm the association between dermopathy and 
incidence of  retinopathy and nephropathy in the pa-
tients with type 2 diabetes and also to investigate some 
dermopathy-associated demographic characteristics.
3. Patients and Methods
This descriptive-analytical study was conducted on 
all diabetes patients admitted to Imam Ali clinic of 
Shahrekord from 2012 to 2014. The inclusion crite-
ria into the study were suffering from type 2 diabetes 
and incidence of  skin lesions characterized as diabetic 
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dermopathy. Other diabetes patients and the patients 
unwilling to participate in the study were excluded. 
The sample size was determined as 102 individuals 
with reference to a previous study (23) and sample 
size formula.
For this study, 102 patients with type 2 diabetes and 
diagnosed with dermopathy by clinical examination 
were enrolled. These patients were examined for de-
mographic characteristics, hypertension, and diabetic 
dermopathy lesions in both legs and the data were re-
corded in a researcher-developed checklist.
The patients were referred to an ophthalmologist to 
be examined for retinopathy and its type. Also 24-
hour urine test was asked from the patients to measure 
their proteinuria, urine volume, and creatinine for ne-
phropathy diagnosis and determination of  its severity. 
The patients with nephropathy were divided into two 
groups based on 24-hour urine protein amount, mild 
nephropathy and severe. In addition, fasting blood 
sugar (FBS) and HbA1c were measured. 
3.1. Ethical issues
1) The research followed the tenets of  the Declaration 
of  Helsinki; 2) informed consent was obtained, and 
they were free to leave the study at any time; and 3) 
the research was approved by the ethical committee of 
Shahrekord University of  Medical Sciences.
3.2. Statistical analysis
The data were encoded and entered into SPSS 18. For 
data analysis, descriptive and analytical (independent t 
test, chi-square, Mann-Whitney U test, and Pearson’s 
correlation coefficient) statistical tests were used and 
P value less than 0.05 was considered as significant.
4. Results
Of  102 patients in this study, 64 (62.7%) were women. 
The patients aged 38-80 years old with mean age of 
60.2 ± 8.38 years. Of  the patients, 63.7% had hyper-
tension and 71 (69.6%) had family history of  diabetes. 
Mean duration of  diabetes was reported 9.16 ± 5.24 
(range: 1-30) years. Most (62.7%) patients used oral 
medications to control diabetes and the rest took insu-
lin. Mean level of  FBS and HbA1c was 123.14 ± 48.87 
mg/dL and 7.29 ± 1.24 % respectively.
In this study the mean proportion of  dermopathy le-
sions was 9.7 ± 5.34. Of  34 (33.3%) patients with ne-
phropathy, 21 had mild dermopathy and the rest had 
severe dermopathy. Retinopathy was diagnosed in 32 
(31.4%) patients, 25 of  whom had nonproliferative 
retinopathy and only 7 had proliferative retinopathy. 
Independent t test was used to compare the mean pro-
portion of  lesions in the patients with concurrent der-
mopathy and retinopathy and those with dermopathy 
alone, and confirmed a significant association between 
dermopathy and retinopathy (P < 0.001). The associa-
tion between mean proportion of  lesions in the pa-
tients with concurrent dermopathy and nephropathy 
and those with dermopathy alone was examined by in-
dependent t-test and a significant association between 
dermopathy and nephropathy was seen (P < 0.001). 
Furthermore, a significant association between insu-
lin injection and proportion of  dermopathy lesions 
was detected (P < 0.05). Likewise, the proportion of 
lesions in the patients with dermopathy was not sig-
nificantly associated with gender and hypertension 
history (P > 0.05; Table 1).
Pearson’s correlation coefficient was used to examine 
the association between the number of  dermopathy 
lesions and body mass index (BMI), duration of  dia-
betes, age, and FBS and HbA1c levels and confirmed 
a significant association between the number of  these 
lesions and duration of  diabetes, age and HbA1c level 
(Table 2). Mann-Whitney test indicated that the num-
ber of  dermopathy lesions was not significantly asso-
ciated with nephropathy severity (P > 0.05).
5. Discussion
The present study was conducted to more precisely 
study and probably confirm an association between 
dermopathy and incidence of  retinopathy and ne-
phropathy in the patients with type 2 diabetes as well 
as to examine some dermopathy-associated demo-
graphic characteristics. The findings demonstrated a 
significant association of  dermopathy with retinop-
athy, nephropathy, age, duration of  diabetes, and 
HbA1c.
Table 1. The association between proportion of  dermopathy 
lesions and the variables under study by independent t test
Variables SD±Mean Proportion of  patients P
Retinopathy 4.85 ± 13.16 32 <0.001
Nephropathy 5.45 ± 12.15 34 0.001
Gendera 5.56 ± 9.75 64 0.896
Hypertension history 3.03 ± 5.15 65 0.055
Insulin intake 2.93 ± 4.40 64 0.030
aFor female participants.
Table 2. The association between proportion of  dermopathy 
lesions and other variables under study by Pearson’s correlation 
coefficient
Variables Pearson's correlation P
Body mass index 0.019 0.851
Duration of  diabetes 0.312 0.001
Age 0.417 <0.001
Fasting blood sugar 0.174 0.080
HbA1c 0.262 0.008
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In this study, the mean age of  the patients was 
60.2 ± 8.83 years and there was a significant association 
between incidence of  diabetic dermopathy and age. In 
other studies, diabetic dermopathy has been report-
ed most prevalent in 45- to 70-year-old patients and 
significantly associated with age (11,14,15,25), as well. 
Further, the mean duration of  diabetes was 9.16 ± 5.42 
years and the number of  dermopathy lesions was sig-
nificantly associated with the duration of  illness, which 
is in agreement with other studies (17,21,26). This con-
sistency of  the findings further confirms the association 
between diabetes duration and the number of  dermopa-
thy lesions. In addition, mean HbA1c level in the present 
study was 7.29 ± 1.24 which was significantly associated 
with the number of  dermopathy lesions. This finding 
confirms other studies’ findings on the association of 
HbA1c with diabetic dermopathy (17,26). Another find-
ing in this study was the significant association between 
diabetic dermopathy and insulin intake, which is in line 
with a study reporting a significantly lower incidence of 
dermopathy in the patients under treatment with insulin 
than those taking oral medications (21). 
Of  102 type 2 diabetes patients with dermopathy stud-
ied in the present study, 32 (31.4%) had diabetic reti-
nopathy, seven of  whom had proliferative retinopathy 
and the rest nonproliferative retinopathy. And a signif-
icant association was seen between dermopathy and 
retinopathy. In a study on 25 type 1 diabetes patients 
with dermopathy, approximately half  (12, 48%) of  the 
patients had retinopathy (27). Also in Abdollahi et al 
study, 30 (44%) patients had concurrent dermopathy 
and retinopathy with a significant association between 
them (24), which is consistent with the present study. 
Another complication examined in the present study 
was nephropathy whose association with diabetic der-
mopathy was studied and a significant association be-
tween diabetic dermopathy and nephropathy was seen 
in the patients with type 2 diabetes. Shemer et al study 
found a significant association between dermopathy 
and nephropathy (21), as well. Moreover Brugler et al 
study reported that 72% of  type 1 diabetes patients 
with dermopathy suffered from nephropathy simul-
taneously (27). 
According to the findings of  the present study, 64 pa-
tients with dermopathy were men and 38 were wom-
en and no significant association between gender and 
proportion of  lesions due to diabetic dermopathy was 
seen. According to the available references, the preva-
lence of  diabetic dermopathy is higher in elderly men 
(28), and some other studies have demonstrated that 
diabetic dermopathy is more prevalent in men with 
a significant association between gender and diabet-
ic dermopathy (11,22,24). These findings are consis-
tent with our investigation, which could be explained 
by lower number of  the men than women referring 
to our clinic. Furthermore, in this study no signifi-
cant association between high BMI and proportion 
of  dermopathy lesions was seen. This finding was 
in agreement with a study of, which considered the 
association between skin lesions, microalbuminoria, 
and other macrovascular complications in the patients 
with type 2 diabetes in 2010. This study showed BMI 
was not associated with dermopathy and other studied 
factors (23).
6. Conclusions
In the present study, a significant association between 
dermopathy and age, duration of  diabetes, retinopa-
thy, and nephropathy was seen. Therefore as the inci-
dence of  diabetic retinopathy and nephropathy is the 
same in the patients with diabetes, it is recommended 
that patients with diabetic dermopathy be examined 
for retinopathy and nephropathy as soon as possible 
so that, these complications could be prevented or 
controlled more efficiently.
Limitations of  the study
Low proportion of  male patients with type 2 diabetes 
referred to the clinic was the limitation of  this study.
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